GSK3A and Alzheimer disease: Of note, overexpression and overactivation of GSK3α/β were observed in the brains of AD patients (Pláteník et al., 2014; Zhou et al., 2022), suggesting that targeting GSK3α/β is an attractive strategy for treating AD.